Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23732384 | 1.00 | GPR119 (0.58) | GPR119POLBMAPTALDH1A1LMNA | |
| SCHEMBL22567334 | 0.84 | GPR119 (0.59) | GPR119POLBMAPTALDH1A1LMNA | |
| SCHEMBL2450769 | 0.83 | GPR119 (0.53) | GPR119POLBMAPTALDH1A1LMNA | |
| SCHEMBL20511076 | 0.82 | GPR119 (0.67) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL27399965 | 0.82 | GPR119 (0.67) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL23701439 | 0.82 | MAPT (0.52) | POLBMAPTALDH1A1LMNAMEN1 | |
| SCHEMBL23732385 | 0.81 | GPR119 (0.53) | GPR119POLBMAPTALDH1A1LMNA | |
| SCHEMBL31055744 | 0.81 | GPR119 (0.53) | GPR119POLBMAPTALDH1A1LMNA | |
| SCHEMBL22523841 | 0.81 | GPR119 (0.52) | GPR119MAPTALDH1A1LMNALIPE | |
| SCHEMBL22015318 | 0.81 | GPR119 (0.52) | GPR119MAPTALDH1A1LMNALIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | GPR119 2107/4885POLB 2518/4885MAPT 4829/4885 |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | LOX, LOXL1, LOXL3 | GPR119 2107/4885POLB 2518/4885MAPT 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.